96 related articles for article (PubMed ID: 11006015)
1. HLA-A2.1/K(b) transgenic murine dendritic cells transduced with an adenovirus encoding human gp100 process the same A2.1-restricted peptide epitopes as human antigen-presenting cells and elicit A2.1-restricted peptide-specific CTL.
Yang S; Linette GP; Longerich S; Roberts BL; Haluska FG
Cell Immunol; 2000 Aug; 204(1):29-37. PubMed ID: 11006015
[TBL] [Abstract][Full Text] [Related]
2. Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells.
Jantscheff P; Spagnoli G; Zajac P; Rochlitz CF
Cancer Immunol Immunother; 2002 Sep; 51(7):367-75. PubMed ID: 12192536
[TBL] [Abstract][Full Text] [Related]
3. Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
Slingluff CL; Colella TA; Thompson L; Graham DD; Skipper JC; Caldwell J; Brinckerhoff L; Kittlesen DJ; Deacon DH; Oei C; Harthun NL; Huczko EL; Hunt DF; Darrow TL; Engelhard VH
Cancer Immunol Immunother; 2000 Mar; 48(12):661-72. PubMed ID: 10752474
[TBL] [Abstract][Full Text] [Related]
4. Antibody-mediated targeting of human single-chain class I MHC with covalently linked peptides induces efficient killing of tumor cells by tumor or viral-specific cytotoxic T lymphocytes.
Oved K; Lev A; Noy R; Segal D; Reiter Y
Cancer Immunol Immunother; 2005 Sep; 54(9):867-79. PubMed ID: 15906027
[TBL] [Abstract][Full Text] [Related]
5. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.
Touloukian CE; Leitner WW; Topalian SL; Li YF; Robbins PF; Rosenberg SA; Restifo NP
J Immunol; 2000 Apr; 164(7):3535-42. PubMed ID: 10725708
[TBL] [Abstract][Full Text] [Related]
6. Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.
Voelkl S; Moore TV; Rehli M; Nishimura MI; Mackensen A; Fischer K
Cancer Immunol Immunother; 2009 May; 58(5):709-18. PubMed ID: 18836718
[TBL] [Abstract][Full Text] [Related]
7. Functional characterization of CTL against gp100 altered peptide ligands.
Dionne SO; Smith MH; Marincola FM; Lake DF
Cancer Immunol Immunother; 2003 Apr; 52(4):199-206. PubMed ID: 12669244
[TBL] [Abstract][Full Text] [Related]
8. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application.
Trevor KT; Cover C; Ruiz YW; Akporiaye ET; Hersh EM; Landais D; Taylor RR; King AD; Walters RE
Cancer Immunol Immunother; 2004 Aug; 53(8):705-14. PubMed ID: 15048588
[TBL] [Abstract][Full Text] [Related]
9. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
[TBL] [Abstract][Full Text] [Related]
10. Establishment of gp100 and MART-1/Melan-A-specific cytotoxic T lymphocyte clones using in vitro immunization against preselected highly immunogenic melanoma cell clones.
Kirkin AF; thor Straten P; Hansen MR; Barfoed A; Dzhandzhugazyan KN; Zeuthen J
Cancer Immunol Immunother; 1999 Aug; 48(5):239-46. PubMed ID: 10478640
[TBL] [Abstract][Full Text] [Related]
11. Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells.
Schuurhuis DH; Lesterhuis WJ; Kramer M; Looman MG; van Hout-Kuijer M; Schreibelt G; Boullart AC; Aarntzen EH; Benitez-Ribas D; Figdor CG; Punt CJ; de Vries IJ; Adema GJ
Cancer Immunol Immunother; 2009 Jul; 58(7):1109-15. PubMed ID: 19018531
[TBL] [Abstract][Full Text] [Related]
12. Proteasomal cleavage does not determine immunogenicity of gp100-derived peptides gp100 209-217 and gp100 209-217T210M.
Nagorsen D; Servis C; Lévy N; Provenzano M; Dudley ME; Marincola FM; Lévy F
Cancer Immunol Immunother; 2004 Sep; 53(9):817-24. PubMed ID: 15133631
[TBL] [Abstract][Full Text] [Related]
13. Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used.
Lesterhuis WJ; Schreibelt G; Scharenborg NM; Brouwer HM; Gerritsen MJ; Croockewit S; Coulie PG; Torensma R; Adema GJ; Figdor CG; de Vries IJ; Punt CJ
Cancer Immunol Immunother; 2011 Feb; 60(2):249-60. PubMed ID: 21069321
[TBL] [Abstract][Full Text] [Related]
14. Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
Sun JY; Senitzer D; Forman SJ; Chatterjee S; Wong KK
Cancer Immunol Immunother; 2003 Dec; 52(12):761-70. PubMed ID: 14564482
[TBL] [Abstract][Full Text] [Related]
15. MHC class II presentation of gp100 epitopes in melanoma cells requires the function of conventional endosomes and is influenced by melanosomes.
Robila V; Ostankovitch M; Altrich-Vanlith ML; Theos AC; Drover S; Marks MS; Restifo N; Engelhard VH
J Immunol; 2008 Dec; 181(11):7843-52. PubMed ID: 19017974
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
Vertuani S; Triulzi C; Roos AK; Charo J; Norell H; Lemonnier F; Pisa P; Seliger B; Kiessling R
Cancer Immunol Immunother; 2009 May; 58(5):653-64. PubMed ID: 18820911
[TBL] [Abstract][Full Text] [Related]
17. Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo.
Whiteside TL; Gambotto A; Albers A; Stanson J; Cohen EP
Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9415-20. PubMed ID: 12080146
[TBL] [Abstract][Full Text] [Related]
18. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy.
Lopes L; Fletcher K; Ikeda Y; Collins M
Cancer Immunol Immunother; 2006 Aug; 55(8):1011-6. PubMed ID: 16311731
[TBL] [Abstract][Full Text] [Related]
19. Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice.
Boesen A; Sundar K; Coico R
Clin Diagn Lab Immunol; 2005 Oct; 12(10):1223-30. PubMed ID: 16210487
[TBL] [Abstract][Full Text] [Related]
20. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]